Biochemical profile of rats with non-alcoholic fatty liver disease of various gravity and its correction with Remaxol

Cover Page

Abstract


Despite the long period of studying non-alcoholic fatty liver disease, its timely diagnosis, prevention and treatment remains one of the most pressing problems of medicine. However, the arsenal of effective and safe medicines used for this task is limited. The goal of this study was to elaborate a model of non-alcoholic fatty liver disease of varying severity in laboratory rats, and to analyze the influence of hepatoprotector medicine Remaxol upon the dynamics of biochemical parameters in experimental groups. The model of non-alcoholic fatty liver disease in laboratory rats permits to reproduce disease of va rying severity: semi–light severity of the disease (non-alcoholic hepatic steatosis) and average degree of severity (nonalcoholic steatohepatitis). The introduction of the test drug was carried out daily during 10 days of experiment starting from day 28th. Used model in experimental animals was characterized by the development of bilirubinemia, cholesterolemia (mainly due to triacylglycerides), activation of peroxidation, cytolytic and cholestatic syndromes. The severity of metabolic disturbances in the rats depended on the severity of the simulated disease. The analysis of the functional activity of the liver changes on the background of the application of Remaxol was performed for 11 parameters, yielding a complete picture of their condition. Distinct therapeutic effect of infusion of Remaxol on the model of liver steatosis (mild fatty liver) and in models of moderate severity (steatohepatitis), aimed at correcting observed violations was demonstrated in the study.


Alexander P. Trashkov

Author for correspondence.
alexandr.trashkov@gmail.com
Sechenov Institute of Evolutionary Physiology and Biochemistry of Russian Academy of Sciences
Russian Federation, Saint Petersburg

MD, PhD, Head of Experimental Pharmacology Dept

Tatiana V. Brus

bant.90@mail.ru
St Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation
Russian Federation, Saint Petersburg

Postgraduate Student, Department of Pathologic Physiology and Course Immunopathology

Andrey G. Vasiliev

avas7@mail.ru
St Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation Saint Petersburg

MD, PhD, Dr Med Sci, Professor, Head, Department of Pathologic Physiology and Course Immunopathology

Margarita R. Artyomenko

shadow_ii@list.ru
Petersburg Nuclear Physics Institute (PNPI) of the National Research Center “Kurchatov Institute” Saint Petersburg

Post-graduate Student, Radiopharmpreparations test center

Valeria A. Pechatnikova

floluttrell@gmail.com
Petersburg Nuclear Physics Institute (PNPI) of the National Research Center “Kurchatov Institute” Saint Petersburg

Research fellow, Radiopharmpreparations test center

Maria A. Gumennaya

magu65110@gmail.com
Petersburg Nuclear Physics Institute (PNPI) of the National Research Center “Kurchatov Institute”
Russian Federation, Saint Petersburg

Junior research fellow, Radiopharmpreparations test center

  • Brunt EM. Non-alcoholic fatty liver disease: what’s new under the microscope? Gut. 2011;60:1152-8.
  • Brunt EM, Wong VW, Nobili V, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1:15080. doi: 10.1038/nrdp.2015.80.
  • Corte С, Nobili V, Alkhouri N, et al. Nonalcoholic fatty liver disease: a challenge for pediatricians. JAMA pediatrics. 2015;169(2):170-176.
  • Goh GB, McCullough AJ. Natural history of nonalcoho lic fatty liver disease. Dig Dis Sci. 2016;61:1226-33. doi: 10.1007/s10620-016-4095-4.
  • Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263-73. doi: 10.1001/jama.2015.5370.
  • Unalp-Arida A, Ruhl CE. Noninvasive fatty liver markers predict liver disease mortality in the U.S. population. Hepatology. 2016;63:1170-83. doi: 10.1002/hep.28390.
  • Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547-55. doi: 10.1053/j.gastro.2014.11.039.

Views

Abstract - 61

PDF (Russian) - 70


Copyright (c) 2017 Trashkov A.P., Brus T.V., Vasiliev A.G., Artyomenko M.R., Pechatnikova V.A., Gumennaya M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.